<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201900</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-J000-342</org_study_id>
    <nct_id>NCT03201900</nct_id>
  </id_info>
  <brief_title>Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients With Partial Onset Seizures (Including Secondarily Generalized Seizures)</brief_title>
  <official_title>A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients With Partial Onset Seizures (Including Secondarily Generalized Seizures)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the seizure-free rate of the 26-week Maintenance Period
      in untreated participants with partial onset seizures (POS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The seizure-free rate during 26-week Maintenance Period for participants with partial onset seizures (POS)</measure>
    <time_frame>up to 26 weeks</time_frame>
    <description>A seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. POS affects only a part of the brain. The outward effect can vary from change in emotions or feelings (simple partial seizure) to loss of awareness and consciousness (complex partial seizure). The percentage of participants with POS who achieved a seizure-free status during the 26-week Maintenance Period of 4 milligrams (mg) will be calculated. For participants for which the perampanel dose is increased from 4 mg to 8 mg, the seizure-free rate of the 26-week Maintenance Period of 8 mg will be evaluated to calculate the percentage of participants who achieved a seizure-free status regardless of perampanel dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The seizure free rate during 52 weeks of treatment (ie, 26-week Maintenance Period plus 26-week Extension Phase) for participants with POS</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>A seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. POS affects only a part of the brain. The outward effect can vary from change in emotions or feelings (simple partial seizure) to loss of awareness and consciousness (complex partial seizure). The percentage of participants with POS who achieved a seizure-free status during 52 weeks of treatment (ie, 26-week Maintenance Period plus 26-week Extension Phase) will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first seizure onset and time to withdrawal from the study from the first date of the Maintenance Period</measure>
    <time_frame>From the start of the Maintenance Period (Week 6) up to 52 weeks</time_frame>
    <description>A seizure is a brief episode of signs or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Median time to first seizure onset will be estimated by Kaplan-Meier method. Median time to withdraw from the study will be estimated by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any treatment-emergent (TE) serious adverse event (SAE) resulting in discontinuation of perampanel</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>An SAE is any untoward medical occurrence that at any dose: results in death; is life threatening (ie, the participant was at immediate risk of death from the adverse events [AE] as it occurred; this does not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any treatment-emergent adverse event (TEAE) resulting in discontinuation of perampanel</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered an investigational product. An AE does not necessarily have a causal relationship with the medicinal product. A TEAE is defined as an AE that emerges during treatment, having been absent at pretreatment (baseline) or (1) reemerges during treatment, having been present at pretreatment (baseline) but stopped before treatment, or (2) worsens in severity during treatment relative to the pretreatment state, when the AE is continuous.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Partial Onset Seizures</condition>
  <arm_group>
    <arm_group_label>E2007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Treatment Phase consists of the 4 milligrams (mg) Treatment Phase (the Titration Period [6 weeks] and the Maintenance Period [26 weeks]) and the 8 mg Treatment Phase (the Titration Period [4 weeks] and the Maintenance Period [26 weeks]) if participants require a higher dose. In the 4 mg Titration Period (6 weeks), participants will initiate 2 mg perampanel once daily (QD) for 2 weeks and then will be up-titrated to 4 mg QD and will continue this dose for 4 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 4 mg Maintenance Period for 26 weeks. Participants will only need the higher dose if they are having seizures. In the 8 mg Titration Period (4 weeks), participants will be administered 6 mg perampanel QD for 2 weeks and then will be up-titrated to 8 mg QD and will continue this dose for 2 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 8 mg Maintenance Period for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>E2007</arm_group_label>
    <other_name>Perampanel</other_name>
    <other_name>Fycompa</other_name>
    <other_name>2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile hydrate (4:3)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be considered reliable and willing to be available for the study period and are able
             to record seizures and report adverse events (AEs) himself/herself or have a caregiver
             who can record seizures and report AEs for them

          -  Participants who are newly diagnosed or recurrent epilepsy and have experienced at
             least 2 unprovoked seizures separated by a minimum of 24 hours in the 1 year prior to
             the Pretreatment Phase

          -  Participants who have excluded the progressive central nervous system (CNS)
             abnormality occurring seizures by computed tomography (CT) or magnetic resonance
             imaging (MRI)

          -  Participants who have had a diagnosis of epilepsy with partial seizures with or
             without secondarily generalized seizures according to the International League Against
             Epilepsy (ILAE) Classification of Epileptic Seizures (1981). Diagnosis should have
             been established by clinical history and an electroencephalogram (EEG) that is
             consistent with localization-related epilepsy; normal interictal EEGs will be allowed
             provided that the participant meets the other diagnosis criterion (ie, clinical
             history)

        Exclusion Criteria:

          -  Participants who present only simple partial seizures without motor signs

          -  Participants who have seizure clusters where individual seizures cannot be counted

          -  Participants who present or have a history of Lennox-Gastaut syndrome

          -  Participants who have a history of status epilepticus

          -  Participants who have a history of psychogenic non-epileptic seizures

          -  Participants who have a history of suicidal ideation/attempt

          -  Participants who present clinically problematic psychological or neurological
             disorder(s)

          -  Evidence of clinically significant disease

          -  Evidence of clinically significant active hepatic disease

          -  A prolonged time from the beginning of the QRS complex to the end of the T wave (QT)
             interval corrected for heart rate

          -  Participants who have a history of receiving any AEDs (except for AEDs used as rescue
             treatment), antipsychotics or anti-anxiety drugs within 12 weeks prior to the
             Pretreatment Phase

          -  Participants who have not used a stable dose of antidepressant in the 12 weeks

          -  Participants who have a history of any type of surgery for brain or central nervous
             system within 1 year

          -  Participants who have a history of receiving any AED (including AED used as rescue
             treatment) for more than 2 weeks

          -  Participants who have used intermittent rescue benzodiazepines on 2 or more occasions
             within 4 weeks

          -  Participants who have a history of receiving any AED polytherapy

          -  Participants who experienced treatment with perampanel

          -  Participants who have had non-constant ketogenic diet within 4 weeks

          -  Participants who have a history of drug or alcohol dependency or abuse

          -  Participants who have had multiple drug allergies or a severe drug reaction to an
             AED(s)

          -  Females who are breastfeeding or pregnant in the Pretreatment Phase (as documented by
             a positive beta-human chorionic gonadotropin [Î²-hCG] test)

          -  Females of childbearing potential who:

               -  Within 28 days before the start of the Pretreatment Phase, did not use a highly
                  effective method of contraception, which includes any of the following:

                    -  total abstinence (if it is their preferred and usual lifestyle);

                    -  an intrauterine device or intrauterine hormone-releasing system (IUS);

                    -  a contraceptive implant;

                    -  an oral contraceptive (with additional barrier method) (Participant must be
                       on a stable dose of the same oral contraceptive product for at least 28 days
                       before dosing and throughout the study and for 28 days after study drug
                       discontinuation);

                    -  have a vasectomized partner with confirmed azoospermia

               -  Do not agree to use a highly effective method of contraception (as described
                  above) throughout the entire study period and for 28 days after study drug
                  discontinuation

          -  Participants who have participated in a study involving administration of an
             investigational drug or device within 4 weeks before Visit 1, or within approximately
             5 half-lives of the previous investigational compound, whichever is longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Customer Joy Department. EJ</last_name>
    <phone>81-3-3817-3700</phone>
    <email>CLNCL@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisai Trial Site</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>perampanel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

